
Marco Pravetoni, PhD
The Pravetoni group focuses on development and translation of medical interventions against substance use disorders (SUD) and other chemical and biological threats. Current efforts are: 1) vaccines, monoclonal antibodies (mAb), and small molecules to treat or prevent SUD, opioid use disorders (OUD) and overdose, 2) mechanisms and biomarkers underlying or predicting efficacy of immunotherapeutics and medications in pre-clinical models of SUD and OUD patients, 3) novel strategies to enhance vaccine or medication efficacy, including immunomodulators, small molecules, adjuvants, nanoparticles, polymers and other delivery platforms, 4) Vaccines, mAb, and clinical biomarkers against infectious diseases (e.g., Pseudomonas aeruginosa and novel coronavirus SARS-CoV-2), 5) biosensors for field detection or diagnosis.
Education
PhD in Pharmacology, University of Minnesota, 2008
Department Affiliations
Scholarly Expertise
- Vaccines, monoclonal antibodies, immunology, pharmacology, chemical threats, immunoprofiling
Recent Publications
(2025 Jul 12)
Biochem Biophys Res Commun 770(): 151995
Hoppe BK, Seaman RW Jr, Hannon B, Gay E, Hicks D, Baehr C, Hill HJ, Pandit SG, Baldridge A, Berner V, AuCoin DP, Runyon S, Pravetoni M
(2025 Apr 16)
Bioconjug Chem 36(4): 676-687
Baehr C, Jahan R, Gebo A, Vigliaturo J, Song D, Rahman MT, Tronconi D, Khaimraj A, Seaman R, Marecki C, Kim CM, Persano S, Runyon SP, Pravetoni M
(2025 Feb 12)
J Immunother Cancer 13(2):
Guevara Lopez ML, Gebo A, Parodi M, Persano S, Maus-Conn J, Mingari MC, Loiacono F, Orecchia P, Sivori S, Cantoni C, Gentili M, Facchinetti F, Ferracini R, Vallera DA, Felices M, Bertolini G, Pravetoni M, Roz L, Vitale M
(2025 Feb 5)
Psychopharmacology (Berl)
Galbo-Thomma LK, Marecki C, Kim CM, Hiranita T, Taylor JR, Maguire DR, Hicks D, Gebo A, Khaimraj A, Baehr C, Pravetoni M, France CP
(2025 Jan 13)
bioRxiv
Hamid FA, Le NN, Song D, Amin H, Hicks L, Bird S, Siram K, Hoppe B, Demeler B, Evans JT, Burkhart D, Pravetoni M
Show complete publication list »